The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | getITD for FLT3-ITD-based MRD monitoring in AML
Lars Bullinger, MD, Charité University of Medicine, Berlin, Germany, outlines the main aims and key findings in the evaluation of the analysis program, getITD, for FLT3-ITD-based minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
